Swedish dendritic and polymeric materials company Polymer Factory Sweden AB (NGM:POLYMER), said on Friday that a study conducted in collaboration with Polymer Factory has uncovered promising results using advanced polymer-based nanocarriers to enhance the efficacy of standard chemotherapy agents.

The research targeted two aggressive and treatment-resistant forms of cancer - glioblastoma and triple-negative breast cancer.

The research focused on two drug delivery systems: polymeric micelles and dendritic nanogels (DNGs) developed with Polymer Factory's proprietary bis-MPA dendritic nanotechnology. These carriers were engineered to encapsulate common cancer drugs, including docetaxel, carboplatin, and doxorubicin.

DNGs demonstrated high loading capacity for water-soluble drugs, while micelles were found to improve solubility and cellular uptake of water-insoluble compounds. The company claims that both systems exhibited strong tumour penetration and significantly suppressed cancer cell growth in laboratory settings.

Traditional chemotherapy often faces limitations such as low solubility, systemic toxicity, and drug delivery barriers like the blood-brain barrier. The nanocarrier systems aim to overcome these issues, potentially improving treatment outcomes for patients.

The results underscore the potential of polymer-based nanotechnology in advancing personalised medicine and enhancing drug delivery strategies for treatment-resistant tumours.